this top growth stock is targeting a multi-billion-dollar market. heres what it means for investors. vertex pharmaceuticals (nasdaq: vrtx) has made a fortune developing medicines for cystic fibrosis (cf) a rare disease that causes damage to the

better growth stock: vertex pharmaceuticals vs. abbvie. vertex pharmaceuticals (nasdaq: vrtx) and abbvie (nyse: abbv) both beat last years bear market. in fact in 2022 these dynamic biotech stocks climbed by percentages in the double digits and

heres how much $100 invested in vertex pharmaceuticals 5 years ago would be worth today. vertex pharmaceuticals (nasdaq:) has outperformed the market over the past 5 years by 5.94% on an annualized basis producing an average annual return of 14.87%. curre

vertex (vrtx) inks licensing deal with crispr for diabetes drug. vertex therapeuticsvrtx announced that it is entering into a new non-exclusive licensing agreement with crispr therapeutics crsp for the use of the latter&rsquo.s gene-ed

ish news may push vertex pharmaceuticals above 52-week high. vertex pharmaceuticals inc. (nasdaq: vrtx) is positioned to make a new run at the 52-week high of $325.19 as the stock is confirming a cup base pattern. the biotechnology company&rsq

vertex crispr therapeutics ink licensing deal for diabetes therapies.

vertex pharma inks licensing agreement to use crispr therapeutics gene editing technology. (rttnews) - biotechnology company vertex pharmaceuticals inc. (vrtx) and gene editing company crispr therapeutics inc. (crsp) announced monday that they h

wall street analysts think vertex energy (vtnr) could surge 61.64%: read this before placing a bet. shares of vertex energy (vtnr) have gained 1.9% over the past four weeks to close the last trading session at $8.03 but there could sti

short interest sector focus: energy sector. as of the close of business on tuesday 3/21 we captured the top 10 highest short interest % stocks within the energy sector. the average short interest for stocks within the energy sector stands at 2.54%. there

bernstein initiates coverage of vertex pharmaceuticals (vrtx) with outperform recommendation. on march 21 2023 bernstein initiated coverage of vertex pharmaceuticals with a outpe

vertex pharmaceuticals for strong cf franchise growth plus exciting pipeline.

: vertex energy stock price target raised to $9.25 from $7.50 at ubs. this is a real-time headline. these are breaking news delivered the minute it happens delivered ticker-tape style. visit www.marketwatch.com or the e page for more information about thi

vertex recent insider activity. ) reported a large insider sell on march 14 according to a new sec filing.

this healthcare company is gearing up for its next launch: here is why the stock is a buy. over the past decade biotech giant vertex pharmaceuticals (nasdaq: vrtx) has made a fortune thanks to its monopoly in treatments for cystic fibrosis (cf).

vertex pharma: fda clears ind application for vx-264. plans to begin phase 1/2 trial in h1. (rttnews) - vertex pharmaceuticals incorporated (vrtx) announced the fda has cleared the investigational new drug application for vx-264 a stem cell-deri

investor alert: law offices of howard g. smith announces investigation of vertex energy inc. (vtnr) on behalf of investors. law offices of howard g. smith announces an investigation on behalf of vertex energy inc. (vertex or the company) (nasdaq: ) inve

vertex (verx) q4 earnings and revenues top estimates. vertex (verx) came out with quarterly earnings of $0.08 per share beating the zacks consensus estimate of $0.05 per share. this compares to earnings of $0.08 per share a year ago. t

vertex q4 profit beats estimates. total revenues up 17.4%. (rttnews) - vertex inc. (verx) posted a fourth quarter net loss of $5.3 million compared to a loss of $627 thousand prior year. net loss per class a share was $0.04 compared to breakeven

zeda inc. (formerly printerprezz / vertex manufacturing) closes $52 million series b financing round. fremont calif. march 07 2023 (globe newswire) -- zeda inc. (previously printerprezz / vertex manufacturing) a global leader in advanced 3d manufactur

(vrtx) - analyzing vertex pharmaceuticalss short interest. ) short percent of float has fallen 11.38% since its last report. the company recently reported that it has

wall street analysts believe vertex energy (vtnr) could rally 30.19%: heres is how to trade. shares of vertex energy (vtnr) have gained 37.3% over the past four weeks to close the last trading session at $9.97 but there could still be

class action lawsuit filed on behalf of vertex energy inc. (vtnr) investors - holzer & holzer llc encourages investors with significant losses to contact the firm. ). the lawsuit alleges vertex energy made materially false and/or misleading statement

entrada therapeutics reports fourth quarter and full year 2022 financial results. - established a transformative collaboration with vertex to discover and develop intracellular endosomal escape vehicle-therapeutics for myotonic dystrophy type 1 - - act

short interest sector focus: energy sector. as of the close of business on thursday 3/2 we captured the top 10 highest short interest % stocks within the energy sector. the average short interest for stocks within the energy sector stands at 2.73%. there

here is why bargain hunters would love fast-paced mover vertex energy (vtnr). momentum investing is essentially the opposite of the tried-and-tested wall street adage -- buy low and sell high. investors following this investing style t

oppenheimer upgrades vertex energy (vtnr). on march 1 2023 oppenheimer upgraded their outlook for vertex energy from perform to outperform.

vertex energy upgraded at oppenheimer as execution gains momentum.

vertex energy surges on q4 beat. to begin renewable diesel output in march.

vrtx crosses below key moving average level. in trading on thursday shares of vertex pharmaceuticals inc. (symbol: vrtx) crossed below their 200 day moving average of $289.69 changing hands as low as $289.58 per share. vertex pharmaceutical

entrada vertex licensing deal on muscle disorder program closes after us antitrust clearance.